86 related articles for article (PubMed ID: 26317170)
21. Predicting the outcome of melanoma: can we tell the future of a patient's melanoma?
Yélamos O; Gerami P
Melanoma Manag; 2015 Aug; 2(3):217-224. PubMed ID: 30190851
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological and Molecular Features of Penile Melanoma With a Proposed Staging System.
Cornejo KM; Goyal A; Valencia Guerrero A; Astudillo M; Dias-Santagata D; Johnson MM; Feldman AS; Hoang MP
Am J Surg Pathol; 2024 May; ():. PubMed ID: 38808927
[TBL] [Abstract][Full Text] [Related]
23. Demographic disparities and survival rates in cutaneous appendageal carcinomas.
Desai AD; Pulumati AL; Ragi SD; Eckembrecher DG; Eckembrecher FJ; Nouri K
Arch Dermatol Res; 2024 May; 316(5):200. PubMed ID: 38775834
[No Abstract] [Full Text] [Related]
24. PAX3d mRNA over 2.76 copies/µL in the bloodstream predicts cutaneous malignant melanoma relapse.
Autilio C; Paolillo C; Lavieri MM; Pocino K; De Paolis E; Di Stasio E; Marchetti P; Gian Carlo CA; Capoluongo E
Oncotarget; 2017 Oct; 8(49):85479-85491. PubMed ID: 29156734
[TBL] [Abstract][Full Text] [Related]
25. New panel of biomarkers to discriminate between amelanotic and melanotic metastatic melanoma.
Militaru IV; Rus AA; Munteanu CVA; Manica G; Petrescu SM
Front Oncol; 2022; 12():1061832. PubMed ID: 36776379
[TBL] [Abstract][Full Text] [Related]
26. MITF in Normal Melanocytes, Cutaneous and Uveal Melanoma: A Delicate Balance.
Gelmi MC; Houtzagers LE; Strub T; Krossa I; Jager MJ
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682684
[TBL] [Abstract][Full Text] [Related]
27. Dedifferentiated Melanoma: A Diagnostic Histological Pitfall-Review of the Literature with Case Presentation.
Cazzato G; Lospalluti L; Colagrande A; Cimmino A; Romita P; Foti C; Demarco A; Arezzo F; Loizzi V; Cormio G; Sablone S; Resta L; Rossi R; Ingravallo G
Dermatopathology (Basel); 2021 Oct; 8(4):494-501. PubMed ID: 34698090
[TBL] [Abstract][Full Text] [Related]
28. Current Molecular Markers of Melanoma and Treatment Targets.
Yang K; Oak ASW; Slominski RM; Brożyna AA; Slominski AT
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429485
[TBL] [Abstract][Full Text] [Related]
29. Integrative analysis of transcriptomics and clinical data uncovers the tumor-suppressive activity of MITF in prostate cancer.
Valcarcel-Jimenez L; Macchia A; Martín-Martín N; Cortazar AR; Schaub-Clerigué A; Pujana-Vaquerizo M; Fernández-Ruiz S; Lacasa-Viscasillas I; Santos-Martin A; Loizaga-Iriarte A; Unda-Urzaiz M; Hermanova I; Astobiza I; Graupera M; Starkova J; Sutherland J; Barrio R; Aransay AM; Carracedo A; Torrano V
Cell Death Dis; 2018 Oct; 9(10):1041. PubMed ID: 30310055
[TBL] [Abstract][Full Text] [Related]
30. Genetic alterations in main candidate genes during melanoma progression.
Sini MC; Doneddu V; Paliogiannis P; Casula M; Colombino M; Manca A; Botti G; Ascierto PA; Lissia A; Cossu A; Palmieri G
Oncotarget; 2018 Feb; 9(9):8531-8541. PubMed ID: 29492214
[TBL] [Abstract][Full Text] [Related]
31. Clinical utilities and biological characteristics of melanoma sentinel lymph nodes.
Han D; Thomas DC; Zager JS; Pockaj B; White RL; Leong SP
World J Clin Oncol; 2016 Apr; 7(2):174-88. PubMed ID: 27081640
[TBL] [Abstract][Full Text] [Related]
32. Triple-marker PCR assay of sentinel lymph node as a prognostic factor in melanoma.
Ito T; Wada M; Nagae K; Nakano-Nakamura M; Nakahara T; Hagihara A; Furue M; Uchi H
J Eur Acad Dermatol Venereol; 2015 May; 29(5):912-8. PubMed ID: 25199412
[TBL] [Abstract][Full Text] [Related]
33. Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy.
Lens MB; Dawes M; Newton-Bishop JA; Goodacre T
Br J Surg; 2002 Oct; 89(10):1223-7. PubMed ID: 12296887
[TBL] [Abstract][Full Text] [Related]
34. Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate.
Balch CM; Gershenwald JE; Soong SJ; Thompson JF
J Surg Oncol; 2011 Sep; 104(4):379-85. PubMed ID: 21858832
[TBL] [Abstract][Full Text] [Related]
35. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
Naffouje S; Naffouje R; Bhagwandin S; Salti GI
Melanoma Res; 2015 Dec; 25(6):496-502. PubMed ID: 26317170
[TBL] [Abstract][Full Text] [Related]
36. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma.
Salti GI; Manougian T; Farolan M; Shilkaitis A; Majumdar D; Das Gupta TK
Cancer Res; 2000 Sep; 60(18):5012-6. PubMed ID: 11016620
[TBL] [Abstract][Full Text] [Related]
37. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
